Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) was down 4% during mid-day trading on Thursday . The stock traded as low as $66.06 and last traded at $66.52. Approximately 14,025 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 27,381 shares. The stock had previously closed at $69.30.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on KRRO shares. Royal Bank of Canada upped their price objective on shares of Korro Bio from $70.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, March 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 target price on shares of Korro Bio in a report on Wednesday, March 27th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $120.00 target price on shares of Korro Bio in a report on Tuesday, March 26th. Finally, HC Wainwright upped their target price on shares of Korro Bio from $100.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, March 28th.
Get Our Latest Analysis on Korro Bio
Korro Bio Stock Performance
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. acquired a new position in Korro Bio during the fourth quarter worth about $12,988,000. Eventide Asset Management LLC acquired a new stake in shares of Korro Bio in the fourth quarter valued at approximately $26,185,000. 72 Investment Holdings LLC acquired a new stake in shares of Korro Bio in the fourth quarter valued at approximately $13,269,000. Point72 Asset Management L.P. acquired a new stake in shares of Korro Bio in the fourth quarter valued at approximately $12,741,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Korro Bio in the fourth quarter valued at approximately $2,784,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.
About Korro Bio
Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Korro Bio
- Comparing and Trading High PE Ratio Stocks
- Comprehensive Analysis of PayPal Stock
- What Are the FAANG Stocks and Are They Good Investments?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- How to Use the MarketBeat Excel Dividend Calculator
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.